|
Name |
10,11-Dihydrobislongiquinolide
|
Molecular Formula | C28H34O8 | |
IUPAC Name* |
(5S)-5-[(2S,4R,7S)-3-[(2E,4E)-hexa-2,4-dienoyl]-6-[(E)-hex-4-enoyl]-5,7-dihydroxy-4,7-dimethyl-8-oxo-2-bicyclo[2.2.2]oct-5-enyl]-4-hydroxy-3,5-dimethylfuran-2-one
|
|
SMILES |
C/C=C/CCC(=O)C1=C([C@]2(C([C@H](C1[C@](C2=O)(C)O)[C@]3(C(=C(C(=O)O3)C)O)C)C(=O)/C=C/C=C/C)C)O
|
|
InChI |
InChI=1S/C28H34O8/c1-7-9-11-13-16(29)18-20-21(28(6)22(31)15(3)24(33)36-28)19(17(30)14-12-10-8-2)26(4,23(18)32)25(34)27(20,5)35/h7-10,12,14,19-21,31-32,35H,11,13H2,1-6H3/b9-7+,10-8+,14-12+/t19?,20?,21-,26-,27+,28+/m1/s1
|
|
InChIKey |
XSCIGHBPJLXBOV-COQTUYRXSA-N
|
|
Synonyms |
10,11-dihydrobislongiquinolide
|
|
CAS | NA | |
PubChem CID | 146683016 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 498.6 | ALogp: | 2.3 |
HBD: | 3 | HBA: | 8 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 138.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 36 | QED Weighted: | 0.193 |
Caco-2 Permeability: | -4.958 | MDCK Permeability: | 0.00006420 |
Pgp-inhibitor: | 0.955 | Pgp-substrate: | 0.669 |
Human Intestinal Absorption (HIA): | 0.023 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.867 | Plasma Protein Binding (PPB): | 89.66% |
Volume Distribution (VD): | 0.729 | Fu: | 10.85% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.269 |
CYP2C19-inhibitor: | 0.018 | CYP2C19-substrate: | 0.713 |
CYP2C9-inhibitor: | 0.005 | CYP2C9-substrate: | 0.044 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.026 |
CYP3A4-inhibitor: | 0.914 | CYP3A4-substrate: | 0.879 |
Clearance (CL): | 7.527 | Half-life (T1/2): | 0.262 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.119 |
Drug-inuced Liver Injury (DILI): | 0.641 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.971 | Maximum Recommended Daily Dose: | 0.916 |
Skin Sensitization: | 0.077 | Carcinogencity: | 0.825 |
Eye Corrosion: | 0.782 | Eye Irritation: | 0.167 |
Respiratory Toxicity: | 0.929 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004086 | 0.776 | D0WY9N | 0.228 | ||||
ENC003579 | 0.727 | D0E9KA | 0.221 | ||||
ENC003250 | 0.667 | D0J2NK | 0.215 | ||||
ENC002144 | 0.500 | D0H2MO | 0.203 | ||||
ENC002133 | 0.455 | D08NQZ | 0.201 | ||||
ENC003762 | 0.447 | D04VEJ | 0.200 | ||||
ENC005696 | 0.422 | D0G4OD | 0.199 | ||||
ENC005202 | 0.401 | D02GAC | 0.199 | ||||
ENC003128 | 0.397 | D0R6RC | 0.199 | ||||
ENC003500 | 0.377 | D03ZFG | 0.198 |